Hitting the nail on the head: Combining oncolytic adenovirusmediated virotherapy and immunomodulation for the treatment of glioma

Wojciech K. Panek, J. Robert Kane, Jacob S. Young, Aida Rashidi, Julius W. Kim, Deepak Kanojia, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Glioblastoma is a highly aggressive malignant brain tumor with a poor prognosis and the median survival 14.6 months. Immunomodulatory proteins and oncolytic viruses represent two treatment approaches that have recently been developed for patients with glioblastoma that could extend patient survival and result in better treatment outcomes for patients with this disease. Together, these approaches could potentially augment the treatment efficacy and strength of these anti-tumor therapies. In addition to oncolytic activities, this combinatory approach introduces immunomodulation locally only where cancerous cells are present. This thereby results in the change of the tumor microenvironment from immune-suppressive to immunevulnerable via activation of cytotoxic T cells or through the removal of glioma cells immune-suppressive capability. This review discusses the strengths and weaknesses of adenoviral oncolytic therapy, and highlights the genetic modifications that result in more effective and targeted viral agents. Additionally, the mechanism of action of immune-activating agents is described and the results of previous clinical trials utilizing these treatments in other solid tumors are reviewed. The feasibility, synergy, and limitations for treatments that combine these two approaches are outlined and areas for which more work is needed are considered.

Original languageEnglish (US)
Pages (from-to)89391-89405
Number of pages15
JournalOncotarget
Volume8
Issue number51
DOIs
StatePublished - 2017

Keywords

  • Checkpoint blockade
  • Combinatory therapy
  • Glioma
  • Immunomodulator(s)
  • Oncolytic adenovirus

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Hitting the nail on the head: Combining oncolytic adenovirusmediated virotherapy and immunomodulation for the treatment of glioma'. Together they form a unique fingerprint.

Cite this